entertainment
LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined the projects in its pipeline.
There was obesity and liver disease, and computational biology and oncology. Then respiratory and inflammatory diseases. And don’t forget mental illness and retinal health. Oh, it was also the day the company launched another Humira biosimilar.
advertisement
In other words, there was a whole lot for the company to discuss as it works to promote its breadth and build partnerships with academic researchers and other companies.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs
Next article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Novavax promises a turnaround & Lilly roils the obesity market
